Figure 6. PRIMA-1^Met suppresses tumor growth in vivo by inhibiting MEK activity.

A. Mice bearing HCT116^neg or HCT116^wt tumors were treated with PBS, PRIMA-1^Met (20 mg/kg or 100 mg/kg). Tumor volume was measured twice a week and data were represented as mean ± SEM. *P<0.05; **P<0.01 vs. vehicle group. B. The body weight of mice in each group was measured and recorded once a week. Data were shown as mean ± SEM. C. Immunohistochemical staining of Ki-67 and phosphorylated ERK1/2 in paraffin embedded sections of tumor xenografts. Scale bar: 50 um. ^*P<0.05; ^**P<0.01. D. The levels ofp-ERK1/2, T-ERK1/2 and p-p90RSK in the dissected xenografts were determined by Western blot analysis.